Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mary Van Zyl"'
Autor:
Emily Alger, Mary Van Zyl, Olalekan Lee Aiyegbusi, Dave Chuter, Lizzie Dean, Anna Minchom, Christina Yap
Publikováno v:
Research Involvement and Engagement, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Background In light of the FDA’s Project Optimus initiative, there is fresh interest in leveraging Patient-reported Outcome (PRO) data to enhance the assessment of tolerability for investigational therapies within early phase dose-finding
Externí odkaz:
https://doaj.org/article/a5cb45ec14b9497e9b1481114ed722e1
Autor:
Mary Van Zyl, Anne Barell, Bridget Cooley, Janet Hanwell, Josie Parlak, Udai Banerji, Johann De Bono, Adam Sharp, Juanita Lopez, Nicolo Matteo Luca Battisti, Anna Minchom
Publikováno v:
Cancer Reports, Vol 7, Iss 6, Pp n/a-n/a (2024)
Abstract Background Though cancer is more prevalent in the older population, this patient group are underrepresented in phase I oncology trials. Aims We evaluated the use of a geriatric screening tool (SAOP3) in patients of 70 years of age or older w
Externí odkaz:
https://doaj.org/article/898ed05cc677458a94115355b7e29a02
Autor:
Mary van Zyl
Publikováno v:
Cancer Nursing Practice. 19:14-15
Autor:
Udai Banerji, J. Hanwell, Mary van Zyl, Wen Xu, Juanita Lopez, Stan B. Kaye, Simon Ward, Johann S. de Bono, Terri P. McVeigh, Anna Minchom, Cathryn A. Moss, Lorraine O'Leary, Elena Cojocaru, Angela George
Publikováno v:
European journal of cancer (Oxford, England : 1990). 114
Background Molecular aberrations in cancer may represent therapeutic targets, and, if arising from the germline, may impact further cancer risk management in patients and their blood relatives. Annually, 600–700 patients are referred for considerat